Tanvex BioPharma, Inc. (6541.TW)

TWD 58.5

(-3.62%)

Revenue Summary of Tanvex BioPharma, Inc.

  • Tanvex BioPharma, Inc.'s latest annual revenue in 2023 was 61.41 Million TWD , up 174.11% from previous year.
  • Tanvex BioPharma, Inc.'s latest quarterly revenue in 2024 Q1 was 3.35 Million TWD , down -63.06% from previous quarter.
  • Tanvex BioPharma, Inc. reported a annual revenue of 22.4 Million TWD in annual revenue 2022, up 314.43% from previous year.
  • Tanvex BioPharma, Inc. reported a annual revenue of 5.4 Million TWD in annual revenue 2021, up 1702.0% from previous year.
  • Tanvex BioPharma, Inc. reported a quarterly revenue of 3.35 Million TWD for 2024 Q1, down -63.06% from previous quarter.
  • Tanvex BioPharma, Inc. reported a quarterly revenue of 9.08 Million TWD for 2023 Q4, up 78.0% from previous quarter.

Annual Revenue Chart of Tanvex BioPharma, Inc. (2023 - 2013)

Historical Annual Revenue of Tanvex BioPharma, Inc. (2023 - 2013)

Year Revenue Revenue Growth
2023 61.41 Million TWD 174.11%
2022 22.4 Million TWD 314.43%
2021 5.4 Million TWD 1702.0%
2020 300 Thousand TWD 0.0%
2019 - TWD 0.0%
2018 - TWD 0.0%
2017 - TWD 0.0%
2016 - TWD 0.0%
2015 - TWD 0.0%
2014 - TWD 0.0%
2013 - TWD 0.0%

Peer Revenue Comparison of Tanvex BioPharma, Inc.

Name Revenue Revenue Difference
Apex Biotechnology Corp. 1.67 Billion TWD 96.337%
Sinphar Pharmaceutical Co.,Ltd. 2.96 Billion TWD 97.927%
Panion & Bf Biotech Inc. 1.88 Billion TWD 96.737%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. 2.08 Billion TWD 97.057%
GenMont Biotech Incorporation 318.01 Million TWD 80.689%
Abnova (Taiwan) Corporation 382.05 Million TWD 83.926%
Adimmune Corporation 1.78 Billion TWD 96.56%
Polaris Group 7.48 Million TWD -720.893%
Energenesis Biomedical CO.,LTD. 7.15 Million TWD -757.935%
UnicoCell Biomed Co., Ltd. 24.58 Million TWD -149.75%
PELL Bio-Med Technology Co. Ltd. 18.03 Million TWD -240.548%